Endocannabinoids New Targets for Drug Development
Authors: Marzo, V.D.; Bisogno, T.; Petrocellis, L.D.
Source: Current Pharmaceutical Design, Volume 6, Number 13, 1 September 2000 , pp. 1361-1380(20)
Publisher: Bentham Science Publishers
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
The possible therapeutic use of marijuanas active principles, the cannabinoids, is currently being debated. It is now known that these substances exert several of their pharmacological actions by activating specific cell membrane receptors, the CB 1 and CB 2 cannabinoid receptor subtypes. This knowledge led to the design of synthetic cannabinoid agonists and antagonists with high therapeutic potential. The recent discovery of the endocannabinoids, i.e. endogenous metabolites capable of activating the cannabinoid receptors, and the understanding of the molecular mechanisms leading to their biosynthesis and inactivation, opened a new era in research on the pharmaceutical applications of cannabinoids. Ongoing studies on the pathological and physiological conditions regulating the tissue levels of endocannabinoids, and on the pharmacological activity of these compounds and their derivatives, may provide a lead for the development of new drugs for the treatment of nervous and immune disorders, cardiovascular diseases, pain, inflammation and cancer. These studies are reviewed in this article with special emphasis on the chemical features that determine the interaction of endocannabinoids with the proteins mediating their activity and degradation.Keywords: Endocannabinoids; Targets Drug Development; marijuana s active principles; Cannabinoids; CB1 cannabinoid receptor subtypes; CB2 cannabinoid receptor subtypes; synthetic cannabinoid agonists; antagonists; therapeutic potential; Endocannabinoids; Nervous; Immnue disorders; Cardiovascular diseases; Pain; Inflammation; Cancer; Polyunsaturated fatty acids (PUFAs); Cannabis sativa; Anandamides; Ethanolamides; Arachidonate homologue; Immunoassays; Anandamide; 2 Arachidonoyl glycerol; PHARMACOLOGICAL; Tetrahydrocannabinol; Central nervous system; Endo Cannabinoid; Aging; Cronic THC treatment; LPS treatment; IgE challenge; Nociceptive stimulus; Epidermal cells; Blood Cells; Reproductive System; Cell Damage; BIOSYNTHESIS; Degradation; Lipase; MAG lipase; The Anandamide Membrane Transporter; FAAH; Anandamide analogues; Anandamide transporter; Amide hydrolase; Fatty Acid; Vanilloids
Document Type: Review article
DOI: 10.2174/1381612003399365
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help